Children/youth with chemotherapy induced peripheral neuropathy (CIPN) experience many impairments, activity limitations, and participation restrictions.
The objective of this study was to describe the use and feasibility of selected multi-dimensional outcome measures of functioning, disability, and health in children/youth with CIPN following treatment for acute lymphoblastic leukemia.
A selection of clinician evaluated and patient reported outcome measures encompassing all dimensions of the International Classification of Functioning, Disability and Health was collected from seventeen children/youth with CIPN within a study of 3D instrumented motion analysis. Measures included the pediatric modified Total Neuropathy Scale, ankle strength and range of motion, six-minute walk test, Edinburgh Visual Gait Score, Oxford Ankle and Foot Questionnaire, Bruininks-Oseretsky Test of Motor Proficiency running speed and agility subtest, and Pediatric Outcomes Data Collection Instrument Transfers and Basic Mobility, Sports/Physical Functioning, and Pain/Comfort scales.
The measures were shown to be feasible and were able to demonstrate differences compared to normative data. They showed variability within the group of children/youth with CIPN except for the running speed and agility test, which had a floor effect. The Edinburgh Visual Gait Scores correlated significantly (r = −0.668, p <0.001) with the Gait Deviation Index, a summary score of kinematic gait data from the 3D motion analysis study.
These measures can contribute clinical practice, research, and the development of core outcome set registries.
1McMaster Children's Hospital and McMaster University, Hamilton, Ontario, Canada
2McMaster Children's Hospital and McMaster University, Hamilton, Ontario, Canada
3McMaster Children's Hospital and McMaster University, Hamilton, Ontario, Canada
Correspondence: Marilyn Wright, BScPT, MSc, MEd, McMaster Children's Hospital and McMaster University, 237 Barton St, Hamilton, ON L8L 2X2, Canada (email@example.com).
Grant Support: Funding for this study was received from the Pediatric Oncology Group of Ontario.
The authors declare no conflicts of interest.